![logo](/logos/SEEL.webp)
Seelos Therapeutics, Inc.
NASDAQ:SEEL
0.23 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Seelos Therapeutics, Inc. |
Symbool | SEEL |
Munteenheid | USD |
Prijs | 0.228 |
Beurswaarde | 1,590,375 |
Dividendpercentage | 0% |
52-weken bereik | 0.2 - 254.4 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Raj Mehra J.D., Ph.D. |
Website | https://seelostherapeutics.com |
An error occurred while fetching data.
Over Seelos Therapeutics, Inc.
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)